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Abstract
Sleep abnormalities are common in schizophrenia, oftenBackground: 
appearing before psychosis onset; however, the mechanisms behind this are
uncertain. We investigated whether genetic risk for schizophrenia is associated
with sleep phenotypes.
We used data from 6,058 children and 2,302 mothers from the AvonMethods: 
Longitudinal Study of Parents and Children (ALSPAC). We examined
associations between a polygenic risk score for schizophrenia and sleep
duration in both children and mothers, and nightmares in children, along with
genetic covariances between these traits.
Polygenic risk for schizophrenia was associated with increased risk ofResults: 
nightmares (OR=1.07, 95% CI: 1.01, 1.14, p=0.02) in children, and also with
less sleep (β=-44.52, 95% CI: −88.98, −0.07; p=0.05). We observed a similar
relationship with sleep duration in mothers, although evidence was much
weaker (p=0.38). Finally, we found evidence of genetic covariance between
schizophrenia risk and reduced sleep duration in children and mothers, and
between schizophrenia risk and nightmares in children.
 These molecular genetic results support recent findings fromConclusions:
twin analysis that show genetic overlap between sleep disturbances and
psychotic-like experiences. They also show, to our knowledge for the first time,
a genetic correlation between schizophrenia liability and risk of nightmares in
childhood.
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Introduction
Sleep disturbance is very common in psychotic disorders such 
as schizophrenia. For example, a meta-analysis of observational 
studies showed that sleep efficiency and total sleep time are 
diminished in schizophrenia, whilst sleep latency is increased, 
independent of medications1. These findings are supported by 
polysomnography studies2. Similarly, sleep dysfunction is more 
common in individuals at ultra-high-risk for psychosis3, and is 
associated with higher risk of incident psychotic experiences4, 
paranoid thinking5 and hallucinatory experiences6 in population-
based cohort studies.
A recent report from the Twins Early Development Study 
(TEDS) demonstrated that psychotic-like experiences and sleep 
disturbances in adolescence share genetic influences7. Using 
data from 4,800 pairs of twins, they found a mean genetic 
correlation of 0.54 between self-reported paranoia, hallucina-
tions and cognitive disorganisation, and self-reported sleep 
quality and insomnia. Bivariate heritability analyses showed that 
shared genetic influences accounted for on average 65% of the 
phenotypic correlation between phenotypes. This genetic rela-
tionship could be explained in several ways. For example, genetic 
variants could independently influence sleep and psychotic- 
like experiences, both sleep and psychotic-like experiences 
could be affected by a shared genetically influenced process, 
or there could be a causal relationship between sleep and psy-
chotic-like experiences. We aimed to build on these analyses by 
using a polygenic risk score derived from the largest genome- 
wide association study (GWAS) of schizophrenia to date8 to 
investigate the genetic relationship between schizophrenia 
liability, sleep duration and childhood nightmares through two 
complimentary approaches.
First, we examined whether genetic risk for schizophrenia is 
associated with sleep dysfunction during childhood and adult-
hood in the population-based Avon Longitudinal Study of Parents 
and Children (ALSPAC). We did this by combining information 
from the Psychiatric Genomics Consortium (PGC) GWAS into 
a polygenic risk score that indexes cumulative genetic risk for 
schizophrenia. The PGC report a variance explained in schizo-
phrenia by the polygenic risk score at a p-value threshold of 
0.05 of 7%8. This approach has previously shown that genetic 
risk for schizophrenia is associated with phenotypes such as 
cognitive deficits9,10, anxiety and negative symptoms11 during 
childhood and adolescence.
Second, we assessed the genetic covariance between schizo-
phrenia and sleep measures in childhood and adulthood using 
polygenic risk score data to estimate the average genome-wide 
relationship between these phenotypes.
Methods
Cohort description
ALSPAC is a prospective birth cohort study which initially 
recruited 14,541 pregnant women living in the Bristol area in the 
UK, with an expected delivery date from 1st April 1991 to the 
31st December 199212. A total of 14, 676 foetuses were included in 
the initial ALSPAC sample, with 14,062 live births and, of these, 
13,988 were alive after 1 year. At 7 years of age further recruit-
ment occurred, resulting in a total sample size for analyses of 
15,458, with 14,755 live births and 14,701 alive at 1 year. Data has 
been collected on mothers and their offspring via questionnaires, 
clinic visits and other forms of information. The ALSPAC sam-
ple is generally representative of the UK population of the same 
age, although, like many other cohorts, there is over-representation 
of more affluent groups (6.22% with low household income, 
as indicated by free school meals, in ALSPAC compared to 
12.49% in the National Pupil Database) and under-representation 
of non-White minority ethnic groups (96.09% White ethnicity 
in ALSPAC compared to 86.50% in the National Pupil Database)12. 
However, to avoid false positive results from population strati-
fication, our analyses included only those with European 
ancestry. We also excluded those without both the genetic and 
the phenotypic data required, leaving between 5,121 and 6,058 
children and 2,302 mothers in each analysis. Table 1 summa-
rises the number of individuals with data available for each of 
Table 1. Number of genotyped participants with each outcome measure.
Age Outcome measure N1 Percentage female
Children
4 years 9 months Sleep duration 6058 48.6%
5 years 9 months Sleep duration 5641 48.9%
6 years 9 months Sleep duration 5534 48.9%
9 years 7 months Sleep duration 5735 49.4%
11 years 8 months Sleep duration 5170 50.2%
12 years Nightmares 5121 51.1%
Mothers
Average age of 40 years 9 months Sleep duration 2302 100%
1The number of participants with both phenotype and genotype data available
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the outcome measures. Including all the time points examined for 
sleep duration, there were a total of 28,138 data points.
Further details of ALSPAC can be found through the searchable 
data dictionary. Ethical approval for the study was obtained 
from the ALSPAC Ethics and Law Committee and the local 
Research Ethics Committees. Written informed consent was 
obtained from participants or parents of participants, for 
children. Children were invited to give assent where appropri-
ate. Study members have the right to withdraw their consent for 
elements of the study or from the study entirely at any time. 
Full details of the ALSPAC consent procedures are available on 
the study website (http://www.bristol.ac.uk/alspac/researchers/
research-ethics/).
Phenotypic measures
Sleep duration. Information about sleep duration in children 
was obtained from parent-completed questionnaire data col-
lected at the ages of 4, 5, 6, 9 and 11 years. Sleep duration was 
calculated as the difference between reported time that the 
child went to sleep and time they awoke on weekdays.
Sleep duration in the mothers was assessed through question-
naire data collected when they were on average 40.78 years 
old (SD=4.52). Participants were asked how many hours and 
minutes they slept for on work days on average in the last year.
Nightmares. The presence of nightmares was assessed through 
semi-structured interviews with participants at around the age 
of 12 and a half years4,13. Briefly, children were asked questions 
about nightmares, night terrors and sleepwalking since their 
12th birthday, such as “Since your 12th birthday have you had 
any dreams that woke you up? Were they frightening?”. Positive 
responses were followed by further questions to distinguish 
between nightmares and night terrors. These were then rated as 
present, suspected or absent. In this study we use data on night-
mares only as this was associated with psychotic experiences in a 
previous study13, and we wanted to examine whether this 
extended to genetic risk for schizophrenia.
Covariates. We used the child’s sex and age as covariates in the 
analyses of children’s sleep outcomes. We included mother’s 
age as a covariate in the analyses of mother’s sleep duration.
Genetic data
Genetic data for children and mothers was collected in the form 
of blood samples during clinic visits. Genotyping for children 
was conducted using the Illumina HumanHap 550quad chip and 
data was generated by Sample Logistics and Genotyping Facilities 
at the Wellcome Trust Sanger Institute and LabCorp (Laboratory 
Corporation of America) using support from 23andMe. ALSPAC 
mothers were genotyped using the Illumina human660W-quad 
array at Centre National de Génotypage (CNG) and genotypes 
were called with Illumina GenomeStudio.
Quality control measures were conducted, and SNPs were excluded 
based on missingness, Hardy-Weinberg equilibrium P value and 
minor allele frequency. Samples were excluded based on gender 
mismatches, indeterminate X chromosome, minimal or excessive 
heterozygosity, disproportionate missingness, insufficient sam-
ple replication and evidence of population stratification. A total 
of 9,115 children and 500,527 SNPs passed the filters and data 
was imputed with a phased version of the 1000genomes reference 
panel from the Impute2 reference data repository. 9,048 
mothers and 526,688 SNPs passed the filters and data was 
imputed using Impute V2.2.2 against the reference panel (all 
polymorphic SNPs excluding singletons), using all 2186 
reference haplotypes (including non-Europeans). After these pro-
cedures, removing participants with cryptic relatedness >5% and 
those who had withdrawn consent, there were 8,252 children and 
8,252 mothers with genotype data available.
Polygenic risk score construction
We constructed polygenic risk scores using Plink version 1.914 
for each individual using summary statistics from the PGC 
schizophrenia GWAS8. SNPs with an imputation quality score 
greater than 0.9 and which were available in ALSPAC were 
clumped for linkage disequilibrium (LD), using an R2 of 0.25. 
We generated weighted polygenic risk scores by summing the 
number of risk alleles present for each SNP (0, 1 or 2) weighted 
by the logarithm of its discovery sample odds ratio (OR). 
For estimating covariance (see below) we constructed twelve 
polygenic risk scores based on different thresholds of the schizo-
phrenia GWAS p-values (1×10−7 to 0.5). The score constructed 
with a p-value threshold (pT) of 0.05 captured the most variance 
in genetic liability for schizophrenia in the PGC sub-datasets8, 
so we used this as our primary exposure, with the remainder 
reported in Extended data Table 1 and Extended data Figure 115. 
Polygenic risk scores were z-standardised, so effect sizes are 
given per standard deviation (SD) increase in polygenic risk score.
Statistical analysis
Association between polygenic risk score and sleep pheno-
types. We conducted statistical analyses in R version 3.2.216 
and Stata version 14.217. First, we investigated the asso-
ciation between the polygenic risk score for schizophrenia 
liability and sleep duration in childhood, by combining all time 
points into one stacked dataset. We used a linear mixed-effects 
model, with age nested within family ID as a random effect and 
covariates age, age2 and sex. We tested for an association between 
the polygenic risk score for schizophrenia liability and night-
mares using an ordinal model with sex as a covariate. We tested 
the association between the polygenic risk score for schizo-
phrenia liability and sleep duration in mothers using a linear 
model with age as a covariate. To estimate the variance explained 
by the schizophrenia polygenic risk score at pT 0.05 for each 
outcome we obtained r-squared values from models without 
covariates; an adjusted r-squared was obtained from the linear 
model, a pseudo r-squared was obtained from the ordinal 
model and a marginal r-squared (the proportion of variance 
explained by the fixed factors) was obtained for the linear 
mixed-effects model.
Estimating genetic covariance between schizophrenia liabil-
ity and sleep phenotypes in childhood and adulthood. Because 
individual level data were available for the sleep phenotypes 
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and summary data were available for the schizophrenia phe-
notype, we used the Additive Variance Explained and Number 
of Genetic Effects Method of Estimation (AVENGEME)18 
to estimate the genetic covariance between schizophrenia liabil-
ity and sleep duration and schizophrenia liability and nightmares 
in children, and between schizophrenia liability and sleep dura-
tion in mothers. To estimate a genetic model AVENGEME used 
the T-scores from results of the association between a series of 
polygenic risk scores at different discovery sample thresholds and 
the outcomes, sample sizes from the training and test samples, 
the number of variants used to create the scores, the p-value 
thresholds used to create the scores and the population prevalence 
of schizophrenia (we used 0.04) and case/control sampling 
fractions for the PGC data (0.43). Using this information, the 
approach is able to estimate the variance explained by genetic 
effects in the training sample, the variance explained by the 
polygenic risk score in the outcomes in ALSPAC, the genetic 
covariance between the training and target samples and the pro-
portion of null SNPs with no effect on the trait in the training 
sample.
Results
Association between polygenic risk of schizophrenia and 
sleep phenotypes
Sleep duration in children. We found that a 1SD increase in 
the schizophrenia polygenic risk score was associated with a 
decrease in sleep duration of 44.52 seconds (95% CI: −88.98, 
−0.07; p=0.05) (Table 2). This was consistent across other poly-
genic risk score thresholds (pT 0.01–0.5) (Extended data, Table 1 
and Extended data, Figure 115). Examining sleep duration at 
different ages indicates that the effect size increases after age 5 
(Extended data, Table 215), although there was little evidence of 
an interaction between polygenic risk and age when an interaction 
term was added to the mixed-effects model (p=0.23).
Nightmares in children. We found evidence of increased risk of 
nightmares in those with greater polygenic risk (OR=1.07; 95% 
CI: 1.01, 1.14; p=0.02) (Table 2). We found a similar pattern 
for other polygenic risk score thresholds (0.05–0.5) (Extended 
data, Table 4 and Extended data Figure 215). We found no evidence 
that the proportional odds assumption was violated (p=0.89).
Adjusting for the mothers’ polygenic risk score in the analyses 
for sleep duration and nightmares in children had minimal 
effect (Extended data Tables 3 and 515), indicating that the 
association is not confounded by the mother’s psychopathology.
Sleep duration in mothers. The effect size of the association 
between schizophrenia polygenic risk score and sleep duration 
in mothers was similar to that seen in children, although 
evidence in support of this association was extremely weak 
(β=-57.90 seconds; 95% CI: −186.57, 70.76; p=0.38) (Table 2), 
most likely because the smaller sample size in the mothers’ 
cohort led to lower power and less precise estimates. The 
results in mothers for other polygenic risk score thresholds can 
be seen in Extended data Table 6 and Extended data Figure 315, 
where scores calculated at more stringent p-value thresholds 
showed small positive associations (1×10-7 to 0.01) compared with 
small negative associations for pT 0.5 to 0.01.
Genetic overlap between sleep phenotypes and 
schizophrenia risk
In the ALSPAC children, our AVENGEME analyses indicate 
a positive covariance between nightmares and genetic liability 
for schizophrenia (covariance= 0.07, 95% CI: 0.05, 0.10). We 
found a negative covariance between sleep duration and genetic 
liability for schizophrenia in children (covariance= −0.008, 95% 
CI: −0.20, −0.003) and between sleep duration and genetic 
liability for schizophrenia in mothers (covariance= −0.04, 95% 
CI: −0.07, −0.01) (see Extended data Table 715 for full results).
Discussion
We investigated whether genetic risk for schizophrenia is associ-
ated with sleep outcomes during childhood and adulthood. Our 
results demonstrate, for the first time with molecular genetic 
data, that greater polygenic risk for schizophrenia is associ-
ated with shorter sleep duration, and we report a new association 
between greater polygenic risk of schizophrenia and increased 
risk of nightmares in early life.
These results build on previous twin study findings of shared 
genetic effects between schizophrenia and disrupted sleep7 by 
showing that the association extends to collections of known and 
measured DNA variants identified through recent well-powered 
GWAS studies.
The effect size of schizophrenia genetic risk on sleep dura-
tion in childhood in this study is small, equating to only a few 
minutes of sleep difference between individuals scoring three 
standard deviations above, compared to individuals scoring three 
standard deviations below the mean for polygenic risk. This is 
likely to reflect both measurement error in the parent-reported 
outcome measures, measurement error in the estimation of the 
Table 2. Associations between schizophrenia polygenic risk (pT 0.05) and sleep 
outcomes.
Sleep phenotype (units) Beta or OR 95% CI R-squared1 P-value
Sleep duration in children (seconds) -44.52 -88.98, -0.07 0.0002 0.05
Nightmares in children (ordinal, OR) 1.08 1.01, 1.14 0.001 0.02
Sleep duration in mothers (seconds) -57.90 -186.59, 70.76 0.00004 0.34
1The r-squared values were a marginal r-squared (the proportion of variance explained by the fixed 
effects) for sleep duration in children, Nagelkerke’s pseudo r-squared for nightmares and the adjusted 
r-squared for sleep duration in mothers.
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effect sizes of the individual DNA variants that make up the 
polygenic score, and the fact that the pool of variants for the 
polygenic score is itself an incomplete set of human genomic 
variation, where many of the variants are imperfect proxies for 
true causal variants. Because of this, it seems likely that 
this small effect size is indicative of the stronger polygenic 
association reported by twin studies. Similarly, although we 
have reported results for sleep duration, we have no direct meas-
ure of sleep quality, so the marginally lower duration of sleep 
may index greater disruption in sleep architecture that could 
have important effects on psychopathology. The R2 value for 
sleep duration indicates that the schizophrenia polygenic risk 
score explains 0.02% of the variation in sleep. To put this into 
context, the PGC article reports that 7% of the variation in 
schizophrenia is explained by the polygenic risk score8. In cross- 
disorder analyses, the schizophrenia polygenic risk score 
explains smaller amounts of variation ranging from 0.08% for 
autism spectrum disorder to 2.3% for bipolar disorder19, 
with similarly low variance explained for cognition (<1%)10. 
Therefore, whilst we find a small amount of variation explained 
in sleep duration, this is on a similar scale to other cross-disorder 
analyses.
We were, however, able to combine measures of sleep duration 
from several different ages, which is likely to have reduced error 
that was not shared across measurement occasions. In addition, 
the data we used were from a population-based sample that is 
less likely to be subject to some of the biases associated with 
ascertainment of clinical samples.
Whilst these findings provide evidence of some underlying 
shared genetic mechanism between sleep phenotypes and 
schizophrenia, they do not allow us to determine the reason 
behind these associations. They could be due to pleiotropy, the 
phenotypes lying on a causal pathway, population stratification 
(although this is less likely due to restriction to those with a 
European ancestry) or a third unknown variable that causes 
both outcomes, where the PGC schizophrenia GWAS may 
have an ascertainment bias based on recruitment of those 
who had experienced this third variable.
Recent studies indicate that there may be a causal relationship. 
For example, a trial of cognitive-behavioural therapy for insom-
nia in people with psychosis reported a decrease in persecutory 
delusions, hallucinations, anxiety and depression20, suggesting 
a causal effect of sleep dysfunction on psychopathology 
post-onset of psychosis. However, another study reported more 
mixed results with psychosis symptoms21, and effects of sleep 
disturbance on incidence of psychosis might differ from those 
on illness severity. Randomised control trials that examine the 
impact of sleep interventions on psychosis incidence are not 
feasible given the incidence rate of psychotic disorders. Our 
results seem to mostly suggest the direction described in the 
first study, where disturbed sleep may result in increased risk for 
schizophrenia as our study finds associations with disturbed 
sleep in childhood and adolescence prior to any disorder 
and the association is with schizophrenia risk. However, it is 
possible that the reverse direction could be true if schizophre-
nia risk results in sub-clinical symptoms that cause disturbed 
sleep. There could also be a bi-directional causal association 
present or no causal association at all. Future well-powered 
analyses using techniques such as Mendelian randomisation 
will be useful for examining whether relationships are causal 
and the direction of causality.
Conclusion
Our results use molecular data to support and extend the find-
ings from twin studies of an overlap of genetic influences on 
sleep phenotypes and schizophrenia. We have presented novel 
findings with our use of polygenic risk scores that specifically 
relate to liability for schizophrenia risk, as opposed to psychotic 
experiences. In addition, we found a novel relationship of shared 
genetic influences between schizophrenia and nightmares in 
children.
Data availability
Underlying data
The ALSPAC data management plan (http://www.bristol.ac.uk/
alspac/researchers/data-access/documents/alspac-data-man-
agement-plan.pdf) describes in detail the policy regarding data 
sharing, which is through a system of managed open access. 
The steps below highlight how to apply for access to the data 
included in this paper and all other ALSPAC data. The datasets 
used in this analysis are linked to ALSPAC project number 
B2172; please quote this project number during your application.
1.    Please read the ALSPAC access policy (PDF, 627 kB) 
which describes the process of accessing the data and 
samples in detail, and outlines the costs associated with 
doing so.
2.    You may also find it useful to browse the fully search-
able ALSPAC research proposals database, which lists 
all research projects that have been approved since 
April 2011.
3.    Please submit your research proposal for considera-
tion by the ALSPAC Executive Committee. You will 
receive a response within 10 working days to advise you 
whether your proposal has been approved.
If you have any questions about accessing data, please email 
alspac-data@bristol.ac.uk.
Extended data
Extended data Tables 1–7 and Figures 1–3 are available via 
the Open Science Framework: Schizophrenia liability shares 
common molecular genetic risk factors with sleep duration and 
nightmares in childhood. DOI: http://www.doi.org/10.17605/OSF.
IO/HPZ5Y15.
Supplementary Table 1. Associations between standardised 
schizophrenia polygenic risk score and sleep duration in children 
in ALSPAC.
Supplementary Table 2. Results from linear regressions for sleep 
duration and polygenic risk score for schizophrenia at each 
of five time points in childhood in ALSPAC.
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Supplementary Table 3. Associations between standardised 
schizophrenia polygenic risk score and nightmares in children in 
ALSPAC.
Supplementary Table 4. Associations between standardised 
schizophrenia polygenic risk score and sleep duration in children 
in ALSPAC, whilst adjusting for mother’s polygenic risk at 
the same threshold.
Supplementary Table 5. Associations between standardised 
schizophrenia polygenic risk score and nightmares in children in 
ALSPAC, whilst adjusting for mother’s schizophrenia polygenic 
risk score at the same threshold.
Supplementary Table 6. Associations between schizophrenia 
polygenic risk score and sleep duration in mothers in ALSPAC.
Supplementary Table 7. Results from estimating a polygenic 
model using AVENGEME, with T-scores from the observational 
associations and the same 12 thresholds used for the polygenic 
risk score construction.
Supplementary Figure 1. Associations between polygenic risk 
score for schizophrenia at 12 different p-value thresholds and sleep 
duration in children in ALSPAC.
Supplementary Figure 2. Associations between polygenic risk 
score for schizophrenia at 12 different p-value thresholds and 
nightmares in children in ALSPAC.
Supplementary Figure 3. Associations between polygenic risk 
score for schizophrenia at 12 different p-value thresholds and 
sleep duration in mothers in ALSPAC.
Data are available under the terms of the Creative Commons Zero 
“No rights reserved” data waiver (CC0 1.0 Public domain dedica-
tion).
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Version 1
 22 February 2019Referee Report
https://doi.org/10.21956/wellcomeopenres.16430.r34686
   Victoria Garfield
Department of Behavioural Sciences & Health, University College London, London, UK
This study used data from the well-known ALSPAC cohort to investigate whether there is shared genetic
aetiology between sleep duration and nightmares, and schizophrenia liability, as sleep disturbances are
common in schizophrenia. The authors used data from both mothers and children and implemented
well-established methods for genetic analyses. Overall, this study is interesting, clearly written and
well-conducted, but there are some important concerns that need to be addressed before indexing.
Major points:
I am not sure about the GWAS data that has been used for creating the schizophrenia polygenic
risk scores, although I am aware that this is the best that is available. In particular, I am unsure of
how valid it is here to weight child polygenic risk scores by effects from a (case-control) GWAS in
adults, particularly for a disorder like schizophrenia, which is also much more likely to be
diagnosed in adulthood. Could the authors comment on this and in their response, detail whether
this was given any consideration and whether they think this is important? If they believe it not to be
as important or have affected any of the results, I think an explanation should be provided.
 
There is no real acknowledgement in the Discussion section on the potential limitations of having
used subjective sleep data for both mothers and children. Regarding the data in mothers, I know
that all that was available was one timepoint, but it is important to acknowledge and briefly discuss
that self-reported sleep data may be prone to error and some bias. There are plenty of studies to
cite which show that the agreement between subjective and objective sleep duration data in adults
is, at best, modest. Furthermore, the sleep data in mothers was only available when they were
aged around 40 years, which is also important to acknowledge, as sleep duration changes
throughout the life course and for example, mothers who have young children are less likely to
have ‘normal’ sleep patterns compared to mothers who have older children or no children. Also,
the question on sleep duration only assessed weekday sleep, which is another important thing to
acknowledge and discuss. However, my understanding was that during this data sweep (~40
years) mothers were asked about both weekday and weekend sleep and that a weighted average
was then taken. I also thought that there were sleep and genetic data available on up to ~7000
ALSPAC mothers at this age, so 2,302 seems much smaller. Could the authors please comment
on this, as well as the above points on self-reported sleep?  
In relation to the child sleep data, it is also crucial to acknowledge that parent-reported data can be
problematic (it was very quickly glossed over in the Discussion) and may also not agree with data
collected via objective methods, such as actigraphy. This is because parents may misreport bedtimes
and time they woke up, particularly if their child does not follow the most conventional bedtime, for
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collected via objective methods, such as actigraphy. This is because parents may misreport bedtimes
and time they woke up, particularly if their child does not follow the most conventional bedtime, for
example. Another important thing to consider here is that the question only asked about bedtime and time
they awoke on   and we know that as children get older their bedtimes change and they areweekdays
more likely to go to bed at a different time during the weekend and potentially, wake up at different times.
 
In general, it is important to acknowledge that if subjective and objective sleep measures correlate poorly
then results could be different if objective measures were analysed.
Introduction:
Could the authors provide the age range or mean age of the twins in the previous TEDS study?
 
Methods:
Page 4: sleep duration section – it says that mothers were asked about how long they ‘slept for on 
 days’, should this be ‘week’ days?work
 
Page 4: Covariates – what is the justification for the (quite narrow) choice of covariates? I think this
needs to be included, as there could be other important covariates to consider.
 
Page 4: PRs construction – please could the authors include a reference or very brief reason for
the clumping threshold of 0.25, as well as what your window for inclusion was (in kb)?
 
Results:
I cannot see a table with any sample characteristics anywhere – could the authors please include a
table with at the very least, mean (SD) sleep durations for children at each age, mean (SD) sleep
duration for mothers, %males or females (for children), mean (SD) age? One important reason for
including the mean sleep durations for children and mothers is to see whether they were similar to
the recommended averages for their ages, in line with guidelines for sleep for both children and
adults.
 
I think it’s slightly unclear exactly how the main PRS results were obtained in children – in the
supplementary file there are results presented by age, but the main results presented in Table 2 in
the main text are unclear in terms of the sample used in these analyses. Presumably, there were
some children who were present at 4 years of age but then lost to follow-up? I think that this could
be clearer in terms of who was included in which analyses.
 
Is it correct to say that adjusting for the mother’s PRS and finding very little effect of this on the
results in children shows that the ‘association is not confounded by the mother’s  ’,psychopathology
given that the term psychopathology is broad and does not only encompass schizophrenia? The
mother’s PRS was only a schizophrenia PRS, so would adjusting for this not simply ensure that the
results in children were not affected by the mother’s genetic risk of schizophrenia or similar?
 
Discussion:
Page 6: the authors say that we still do not know the exact mechanisms behind the associations
that they found between schizophrenia and sleep measures. However, wouldn’t these be
extremely difficult to determine for such small effects?
 
Page 6: Could the authors give an example of what sort of ‘third variable’ they are referring to when
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Page 6: Could the authors give an example of what sort of ‘third variable’ they are referring to when
they say that the PGC GWAS may have ascertainment bias?
 
It might be of interest in future to also perform a similar study with fathers/other adult males, as
effects could be different.
 
Also, only sleep duration was examined and other sleep phenotypes may have different
associations with a schizophrenia PRS. There are large-scale GWAS of other sleep phenotypes
available too.
 
The authors have briefly acknowledged that the effect sizes they observed are small. They are,
indeed, very small and a couple of the results have very wide 95% confidence intervals. In light of
these very small effect sizes, could the authors comment, in the Discussion section, on the
potential clinical meaning of these?
 
Supplementary file:
Could the authors please include the R values in each table for each PRS at every threshold? I
think it would be informative for the reader to see how the R varied throughout the different
models.
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